ECA Marcellus Trust I (ECTM)
OTCMKTS · Delayed Price · Currency is USD
0.4830
-0.0067 (-1.37%)
At close: Nov 17, 2026
ECA Marcellus Trust I Revenue
ECA Marcellus Trust I had revenue of $623.00K in the quarter ending September 30, 2026, a decrease of -5.84%. This brings the company's total for the last twelve months to $4.15M, up 16.45% year-over-year. In the year 2025, ECA Marcellus Trust I had annual revenue of $3.76M with 73.05% growth. That makes ECA Marcellus Trust I the 40,611th largest company in the world by revenue and 5,416th in the United States.
Revenue (ttm)
4.15M
Revenue Growth
+16.45%
P/S Ratio
2.05
Revenue / Employee
2.07M
Employees
2
Market Cap
8.50M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.76M | 1.59M | 73.05% |
| Dec 31, 2024 | 2.18M | -709.58K | -24.60% |
| Dec 31, 2023 | 2.88M | -8.74M | -75.18% |
| Dec 31, 2022 | 11.62M | 5.33M | 84.63% |
| Dec 31, 2021 | 6.30M | 4.59M | 269.63% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| EXCO Resources | 394.03M |
| Unit Corporation | 109.80M |
| Pacific Coast Oil Trust | 14.01M |
| Royale Energy | 2.34M |
| Cyber App Solutions | 586.70K |
| Biloxi Marsh Lands | 75.50K |
| Gulf Coast Ultra Deep Royalty Trust | 703.00 |
ECA Marcellus Trust I News
- 4 days ago - ECA Marcellus Trust I Announces Quarterly Distribution - Business Wire
- 2 years ago - Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel) - Business Wire
- 2 years ago - ECA Marcellus Trust I Announces There Will Be No Quarterly Distribution - Business Wire
- 2 years ago - Neurotech Pharmaceuticals, Inc. Receives Priority Review of Biologics License Application (BLA) for NT-501 (revakinagene taroretcel) as a Treatment for Macular Telangiectasia Type 2 (MacTel) - Business Wire
- 2 years ago - Kontron introduces the XMC-ETH6 - Business Wire
- 6 years ago - ECA Marcellus Trust I Provides Update on NYSE Delisting - Business Wire